Background: Anti-epidermal growth factor receptor treatment strategies, i.e. monoclonal antibodies such as cetuximab and panitumumab, or epidermal growth factor receptor (EGFR) small molecule tyrosine kinase inhibitors, such as erlotinib and gefitinib, have expanded the treatment options for different tumor types. Dermatologic toxic effects are the most common side-effects of EGFR inhibitor therapy. They can profoundly affect the patient's quality of life.
introduction
Inhibitors of the epidermal growth factor receptor (EGFR) are used in a growing range of tumor types to improve clinical outcome. EGFR may be inhibited with anti-EGFR-specific monoclonal antibodies or small molecule tyrosine kinase inhibitors. Cetuximab (Erbitux Ò ), a chimeric immunoglobulin G1 monoclonal antibody, and panitumumab (Vectibix 
. Dermatologic toxic effects are the most common side-effects associated with anti-EGFR therapy. EGFR inhibitor-mediated dermatologic side-effects include acneiform skin rash; hyperpigmentation; xerotic skin; pruritus; skin fissures; nail changes; disorders of mucous membranes, eyes and hair-with an incidence ranging from 49% to 100% of patients [1] . Though mild (grade 0-1) to moderate (grade 2) toxic effects are common in cetuximab-or panitumumab-treated patients, 15% of patients experience severe reactions (grade ‡ 3) [2, 3] . A systematic review of published data from 8998 cancer patients treated in prospective clinical trials concluded that there are no reported deaths from skin rash [4] .
Almost all available studies addressing EGFR-inhibitorinduced skin rash suggest that its severity is a suitable surrogate marker for efficacy of anti-EGFR therapy [5] [6] [7] [8] . Racca et al. [9] observed significant correlation between cutaneous toxicity and objective response rate. Recently, a retrospective exploration of several panitumumab trials by Peeters et al. [10] confirmed an association between clinically graded skin toxicity and patientreported outcome, quality of life, longer progression-free survival and overall survival. The authors suggest that skin reactions should be treated while continuing EGFR-targeted therapy. Data from the EVEREST trial [11] and from a phase II trial with FOLFIRI and panitumumab [12] did not show any correlation between skin rash and efficacy of anti-EGFR therapy.
Despite the benefits of anti-EGFR agents, toxic effects of the skin may eventually result in poor patients' compliance, lower adherence to cancer therapy, more dose delays and interruptions or discontinuation of antineoplastic therapy [1, [13] [14] [15] . Finally, toxic effects of the skin may significantly reduce the quality of life [14, 16, 17] . Though potential treatment suggestions for EGFR inhibitor-associated toxic effects of the skin have been evaluated in clinical trials, standard guidelines have not been published so far.
materials and methods and consensus formation panel composition
The panel comprised clinicians and a pharmacist from Germany with expertise in medical oncology, dermatology or clinical pharmacology and special knowledge of the treatment of EGFR-inhibitor-induced skin reactions. 
methods of consensus development
A task force of clinical experts in the fields of medical oncology and dermatology prepared the first manuscript based on the data source described. All members of the panel were asked to agree on a consensus statement following a period of consensus meetings and discussion based on the draft manuscript. The expert opinion represents the German perspective of the management of EGFR-inhibitor-induced skin toxicity and includes personal experiences of the expert panel. All members of the panel participated in the preparation of the final manuscript, which was circulated for review.
results
EGFR-inhibitor-induced toxic effects of the skin are well described and claimed to be a class effect of this substance group [18] . Although rarely life threatening, they can cause significant discomfort and may impact the quality of life and well-being of the patient [4, 14, 16, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Skin toxicity often has a cosmetic and stigmatizing effect leading to low self-esteem and social isolation. Consequently, emotional factors are most significantly affected [16] .
pathophysiological characteristics of skin reactions
The EGFR plays an important role in differentiation and development of skin follicles. EGFR is constitutively expressed by normal epidermal and follicular keratinocytes in the basal layer of the epidermis, in the outer root sheath of hair follicles, in sebaceous and eccrine epithelium; by dendritic cells and various connective tissue cells [23] [24] [25] [26] . EGFR signaling stimulates epidermal growth and differentiation, accelerates wound healing and stimulates vasoconstriction and keratinocyte migration [27, 28] . EGFR stimulation activates phosphatidylinositol turnover, subsequently leading to diacylglycerol formation. During EGFR inhibitor therapy, phosphorylated EGFR is abolished and inflammatory cell chemoattractants like CXCLs and CCLs are released. Inhibitory proteins for growth-like cyclin-dependent kinase inhibitor p27 are upregulated, whereas phosphatidylinositol turnover, diacylglycerol formation, the proliferation marker Ki67 and MAPK expression are reduced [25] . This results in an abnormal maturation and skin differentiation, growth and migration arrest, an increased rate of apoptosis and an inflammatory response leading to tissue damage and skin atrophy. Severe acute skin reactions show massive neutrophilic infiltration of the epidermis and, profound apoptosis [27, 29, 30] . Immunohistochemistry and in situ hybridization reveal an increased expression of p27Kip1 in keratinocytes [31] , whereas chronic skin changes are characterized by epidermal atrophy, disappearance of follicular structures and epidermal fissures [27] . In summary, EGFR inhibitor treatment induces a complex pattern of tissue injury and inflammatory cell recruitment, damaging the basal epidermis, the sweat and sebaceous glands and hair follicles.
clinical presentation of dermatologic toxic effects acneiform rash. Acneiform rash, the most frequent EGFRinhibitor-induced skin toxicity, occurs in 45%-100% of patients [1] and usually develops within the first 2-4 weeks of treatment ( Figure 1 ). Patients present with macular, papular or pustular lesions mainly localized in cosmetically sensitive areas, e.g. regions rich in sebaceous glands like face ( Figure 2 ) and upper trunk but can extend to the extremities, too [22, 32, 33] . In most cases, the rash is mild and well tolerated but tenderness, pain, disfigurement and even acneiform dermatitis worsening to exfoliative dermatitis may occur. The reported incidence of severe skin reactions grade 3/4 is 0%-17%, slightly more seen in patients treated with monoclonal antibodies than in patients treated with EGFR small molecule tyrosine kinase inhibitors [1, 34, 35] . The skin rash associated with EGFR inhibitors is different from acne vulgaris, as there are no comedones. Histopathology confirms a sterile eruption consisting of follicular papules and pustules in an acneiform distribution. Therefore, the term 'acneiform rash' should consequently be used instead of 'acne' or 'acne-like rash' to describe this EGFR-inhibitor-induced skin rash. The rash usually improves with time, but rarely resolves completely as long as EGFR inhibitors are administered. Infectious complications or localized abscesses requiring surgery may occur in patients with an acneiform rash, but a fatal outcome following sepsis, as previously described in one patient, is not a direct consequence of the rash [36] .
photosensitivity. Some patients show widespread erythema, infiltration and pustules in sun-exposed areas, which is attributed to a photosensitizing capacity of the substance class [13, 37, 38] . Higher grades of solar dermatitis with blistering, however, are rare.
pruritus. Pruritus, mostly due to mild exsiccation, develops in 15 % of patients (grade 3/4: 1%), usually 2-3 weeks after the initiation of anti-EGFR therapy [12] . Some patients complain of 'irritation' or 'pain' [39] .
xerotic skin. Xerotic skin occurs in 4%-100% of patients. First symptoms occur after 1-2 months of EGFR inhibitor therapy and tend to increase with time ( Figure 1 ). Dry skin may occur in the face, trunk, extremities and mucous membranes, leading to perineal and vaginal dryness. Osio et al. [17] reported on an incidence of xerotic skin manifestations of 100% in patients treated with EGFR inhibitors for >6 months.
fissures. Painful fissures on the tips of fingers and toes are frequently reported during EGFR inhibitor therapy; the overall incidence is 18% (grade 3/4: 3%) [10, 12, 39] . Fissures are typically located on the fingertips or over the interphalangeal joint of the fingers or toes and are highly associated with xerotic skin [32] . nail changes. Paronychia, an inflammation of the nail folds, is an infrequent, but painful side-effect of EGFR inhibitor therapy [40] . An example of a patient suffering from paronychia is shown in Figure 3 . Paronychia usually does not develop before 4-8 weeks from start of therapy and occurs in 12%-58% of patients. Osio et al. [17] pointed out a frequence of paronychia of >50% for patients on EGFR inhibitors for longer than 6 months. Bacterial and fungal superinfections may stimulate the development of granulation tissue [41] . Therefore, for diagnostics, bacterial and fungal cultures are recommended [39] . In rare cases, onycholysis, partial or complete loss of the nail plate, have been described. hair growth abnormalities. There are single reports of patients developing finer, curlier and brittle scalp hair, as well as localized facial hypertrichosis and trichomegaly especially of the eyelashes, which may occur within a few weeks or months after the start of EGFR inhibitor treatment [42] . Few cases of severe hair disorders, even leading to alopecia of the scalp and beard are reported [32] , but the causal relationship remains unclear.
other EGFR inhibitor-associated dermatologic toxic effects. Other EGFR inhibitor-mediated dermatologic reactions include telangiectasia, hyperpigmentation and disorders of mucous membranes like stomatitis, mucosal dryness and inflammation [22] . eye disorders. Eye disorders that have been reported in patients undergoing EGFR inhibitor therapy include conjunctivitis, blepharitis, dry eyes or increased lacrimation, as well as growth of eyelashes (trichomegaly) [43] .
kinetics and typical time course of skin reactions
Skin reactions tend to start in the second week after initiation of EGFR inhibitor therapy. The onset varies between individuals depending on preexisting skin conditions and the susceptibility of the individuals. Different patterns of skin reactions seem to have their individual characteristic time frame of peak and onset ( Figure 1 ). The acneiform rash is usually first, starting with an acneiform maculopapular rash followed by papulopustular rash and crusting [1, 44] . The severity of the acneiform skin rash usually peaks at 2-3 weeks after initiation of therapy. Pruritus, often associated with xerotic skin and exsiccation dermatitis, typically starts after 2-3 weeks. Fissures do usually not occur before 6-8 weeks of therapy. Paronychia and hair changes may start after 8 weeks of treatment [32, 45] . The median time to resolution after the final dose of EGFR inhibitor is reported to be 28 days [46] .
grading of skin reactions
The National Cancer Institute (NCI) has developed the common terminology criteria for adverse events (NCI-CTCAE), including a grading scale for severity that is widely used for adverse events reported in clinical trials [47, 48] . The NCI-CTCAE version 3.0 grading scale published in 2006 has been used most often for evaluation of EGFR-inhibitor-induced skin toxicity. In addition, acneiform reactions can be accurately followed over time with a skin-lesion-based grading system focusing on treatment results on a long-term objective basis [49] .
The NCI-CTCAE criteria, however, are not optimal for grading EGFR-inhibitor-related toxic effects [50] . An updated 4.0 version has been published recently, but this version again, due to the expert panel's opinion, does not reflect the clinical situation. The relevant criteria of CTCAE versions 3.0 and 4.0 are compared in Table 1 . In the expert panel's opinion, grading for EGFR-inhibitor-induced toxic effects of the skin should be preferably based on the grade of severity and not on the pattern of distribution, i.e. localized versus generalized. Very recently, a skin toxicity study group of the Multinational Association of Supportive Care in Cancer proposed a class-specific grading scale to standardize assessment and to improve reporting of EGFR-inhibitor-associated dermatologic adverse events by detection of dermatologic toxic effects with greater sensitivity, specificity and range [51] .
management guidelines and treatment recommendations
To date, few management guidelines for EGFR-inhibitormediated dermatologic toxic effects are published. Most of them, however, are not evidence based. The management of EGFR-inhibitor-induced skin toxicity is largely empiric and supportive [40] . There are at least three full papers on randomized controlled trials on prophylactic use of oral tetracycline (which indicated that tetracycline may be effective) [52] , topical tazarotene (which stated tazarotene to be ineffective) [53] and topical pimecrolimus (which showed pimecrolimus to be ineffective) [54] .
In the Medline, listed English literature recommendations based on expert consensus meetings were reported from an European view [55] , from an American view [43] and from a Canadian view [56] . In addition, a Swiss oncologicdermatologic consensus statement was recently published [57] .
Various groups published recommendations based on personal experiences [1, 13, 32, [58] [59] [60] .
Most important to know is that EGFR-inhibitor-induced skin reactions can be effectively treated at all stages and at all grades that might occur [27] . All dermatologic effects usually are reversible and generally heal without sequelae within 4 weeks after treatment discontinuation [9] . In most cases, therapeutic benefit has been already observed after 3-5 days and after 1week clinically relevant amelioration has been seen. Due to personal experiences, in most of the patients, dry skin can be observed even weeks or months after end of EGFR inhibitor therapy. Prophylactic treatment has not been entered into routine clinical practice, although first results have pointed out a significant benefit of preemptive treatment [14, [61] [62] [63] [64] .
Treatment recommendations reported here are based on severity, i.e. grade, and stage of dermatologic reaction. They are divided into general recommendations and side-effect-specific recommendations. Importantly, these recommendations do not offer personalized medical diagnosis or patient-specific treatment advice. All decisions regarding patient care must integrate the unique characteristics of the patient and the individuals' response to different treatment modalities. Frequent clinical follow-up by an experienced dermatologist or oncologist is obligatory, i.e. at least every 2 weeks, including immediate consultation if flare-up occurs [22, 32] .
general treatment recommendations
General treatment suggestions include the use of gentle soaps and shampoos, moisturizer treatment, avoidance of sun exposure and use of sunscreen with high sun protection factor (e.g. SPF30) [21, 26, 27, 65, 66] . They are summarized in Table 2 . Treatment that is not recommended and should be avoided is summarized in Table 3 .
treatment recommendations for specific clinical symptoms
There is no specific treatment available; therapeutic options include topical and systemic approaches. In the literature, treatment suggestions include moisturizer, drying agents, mild skin cleansers, topical antiseptics, topical antibiotics, systemic antibiotics and topical or systemic steroids. In general, treatment should be started as early as possible after onset of dermatologic reactions. Our stage-and grade-adapted recommendations are based on time-course-dependent stages of anti-EGFR-induced skin reactions (Table 4) . They are as given below. treatment of acneiform rash. In contrast to acne vulgaris, the skin of patients with an acneiform rash is not seborrhoic and will even become xerotic within a few weeks. Therefore, moisturizing of the skin may be useful. Beginning topical antibiotic treatment with erythromycin, metronidazole or nadifloxacin twice daily is recommended for early-stage and low-grade papulopustular skin reactions [55] . Cream or lotion preparations should be preferred to take advantage of an additional moisturization effect. Systemic treatment should at least be started if skin reactions grade ‡ 2 occur. Topical solutions or alcohol-containing gel formulations should be avoided because they may enhance dryness. Topical corticosteroids are not generally recommended [22, 32] , but may be beneficial especially in a combination regimen with topical antibiotics, e.g. nadifloxacin [68, 69] . Topical hydrocortisone 1% cream or topical calcineurin inhibitors, such as pimecrolimus, were reported to be effective, too [70] . Recently, however, a randomized controlled trial showed pimecrolimus to be ineffective for cetuximab-induced rash [54] .
Oral tetracyclines, such as doxycycline or minocycline, reduce the severity and extent of the acneiform eruption [14, 52, 53] . They are recommended for skin rash grade ‡ 2. Although microbial pathogens are typically absent in earlystage EGFR-inhibitor-induced skin reactions, oral tetracyclines are recommended for their immunomodulating and antiinflammatory effects [71, 72] . The adverse events of minocycline include vestibular dizziness and loss of balance, as well as postinflammatory hyperpigmentation, drug-induced hepatitis and a lupus-like syndrome [73] . Doxycycline exhibits more light sensitizing effects. There is no evidencebased preference for any of the above-mentioned tetracyclines for treatment of anti-EGFR-induced skin rash grade ‡ 2 so far.
secondarily infected rash. Secondary infection of skin rash may occur at later stages, which includes impetiginisation-an important complication caused by staphylococci or streptococci. Staphylococcus aureus is the most frequently detected infectious agent, less frequent infections include herpes simplex, herpes zoster and dermatophytes [74] . Abscesses may require incision and drainage to prevent sepsis. Bacterial swabs should be taken and calculated anti-infective treatment should be started.
treatment of xerotic and eczematous skin. The keystone of treatment of dry skin is to avoid dehydrating body care such as hot showers and excessive use of soaps, and to return moisture by applying emollients. These should be applied at least once daily to the whole body. Inflammatory skin conditions such as eczema and fissures might develop on xerotic skin [66, 75] . Alcohol-containing lotions or gels should be avoided in favor of oil-in-water creams or ointments [1, 55] . Erythema and desquamation are indicative of ongoing eczema and can be treated with topical steroid preparations such as prednicarbate cream. For erythema and/or desquamation, grade 3 short-term oral systemic steroids are recommended.
treatment of pruritus/itching. Skin moisturizer and urea-or polidocanol-containing lotions are suitable to soothe pruritus. Systemic treatment with oral H1-antihistamines such as cetirizine, loratadine, or fexofenadine as well as clemastine may provide relief of itching for patients with grade 2/3 pruritus.
treatment of fissures. Fissures can be treated topically with propylene glycol 50% in water for 30 min under plastic occlusion every night, followed by application of hydrocolloid dressing. Alternatively, antiseptic baths such as potassium permanganate in a concentration of 1 : 10 000 or topical application of silver nitrate solutions may be used to accelerate wound closure [22, 55] . In addition, the surrounding skin Table 2 . General recommendations for prophylaxis while receiving anti-EGFR inhibitor treatment Personal hygiene Use of gentle soaps and shampoos for the body, i.e. pH5 neutral bath and shower formulations and tepid water Use of very mild shampoos for hair wash Only clean and smooth towels are recommended because of potential risk of infection. The skin should be patted dry after a shower, whereas rubbing the skin dry should be avoided Fine cotton clothes should be worn instead of synthetic material Shaving has to be done very carefully Manicure, i.e. cutting of nails, should be done straight across until the nails no longer extend over the fingers or toes.
Cuticles are not allowed to be trimmed because this procedure increases the risk of nail bed infection Sun protection
Sunscreen should be applied daily to exposed skin areas regardless of the season. Hypoallergenic sunscreens with a high SPF (at least SPF30, PAPA free, UVA/UVB protection), preferably broad spectrum containing zinc oxide or titanium dioxide are recommended Patients should be encouraged to consequently stay out of the sun Protective clothing for sun protection and wearing of a hat should be recommended Moisturizer treatment
It is important to moisturize the skin as soon as anti-EGFR therapy is started Hypoallergenic moisturizing creams, ointments and emollients should be used once daily to smooth the skin and to prevent and alleviate skin dryness [ 
67] Prevention of paronychia
Patients should keep their hands dry and out of water if ever possible They should avoid friction and pressure on the nail fold as well as picking or manipulating the nail Topical application of petrolatum is recommended around the nails due to its lubricant and smoothing effects on the skin. Petrolatum prevents evaporation of moisture by forming a film on the surface EGFR, epidermal growth factor receptor. treatment of nail changes. Paronychia should be treated with daily antiseptic baths to avoid bacterial superinfection. Topically povidone-iodine-based ointments could be applied. Hypergranulative tissue formations can be treated with silver nitrate application on a weekly basis. In severe cases, systemic oral antibiotics such as doxycycline or minocycline should be given, but interruption of EGFR inhibitor therapy should be considered only if treatment fails. When bacterial or fungal superinfection is suspected, systemic treatment should be based on the results of bacterial culture [40] . Surgical procedures may be helpful in selected cases [1] .
when to refer to a dermatologist?
The referral to a dermatologist depends on one's own clinical experiences. In general, lesions classified as grade 3 or higher should always be managed collaboratively by an oncologist and a dermatologist. Grade 2 skin reactions may be managed by an oncologist provided he or she has in-depth knowledge and extensive clinical experience in the field of toxic effects of the skin. Otherwise a dermatologist should be consulted. Lesions of any grade with an unusual appearance or distribution should always be examined by a dermatologist. Necrosis, blistering, petechial or purpuric lesions and signs of infection including cellulitis or atypical dermatologic manifestations that might be unrelated to EGFR-inhibitor-induced rash should be immediately examined by a dermatologist.
when to adjust treatment with anti-EGFR monoclonal antibodies?
If a patient experiences a severe skin reaction grade ‡ 3, anti-EGFR monoclonal antibody therapy must be interrupted according to SmPC. Treatment, e.g. with panitumumab or cetuximab, may only be resumed if the reaction has resolved to grade 2 or below.
is prophylactic treatment recommended?
Prophylactic treatment needs to be safe, well tolerated and not interfering with the antitumor effect of EGFR inhibition. There are three randomized controlled studies reported where prophylactic tetracyclines were applied [52, 53, 63, 64] . Jatoi et al. [52] compared tetracycline 500 mg b.i.d. versus placebo and showed that the incidence of skin reactions was similar, but itching and burning were less severe. Scope et al. [53] concluded that oral minocycline may be useful in decreasing severity of acneiform eruption during the first month of cetuximab treatment, while there was an apparent lack of benefit of minocycline beyond 2 months. The STEPP trial, a phase 2, open-label study of prophylactic versus reactive skin toxicity treatment in panitumumab-treated patients with metastatic colorectal cancer revealed a statistically significant reduction of the incidence rates of specific grade 2 or higher review Annals of Oncology toxic effects of the skin of >50% for patients in the prophylactic treatment arm [61] [62] [63] [64] . Prophylactic treatment comprised skin moisturizer, sunscreen (PABA free, SPF ‡ 15, UVA/UVB protection), a topical steroid (1% hydrocortisone cream) and doxycycline 100 mg b.i.d. [14, 64, 76] . An improved quality of life and fewer dose delays were reported in the prophylactic skin treatment arm, while there have been no differences in antineoplastic efficacy [63, 64, 76] . In summary, however, there remain a number of unresolved issues due to prophylactic treatment, e.g. whether or not to give prophylactic agents and, if given, whether to use topical and/or systemic approaches.
conclusion
Dermatologic toxic effects are the most common side-effects of EGFR inhibitor therapy. Patients are frequently unable to cope with these side-effects, leading to poor adherence to cancer therapy, dose reduction, dose interruption or even cessation and potentially a reduced quality of life. To date, there are no evidence-based treatment algorithms for the management or prophylaxis of skin reactions associated with anti-EGFR treatment. Thus, besides a precise grading system, a better treatment plan for managing all grades and forms of these complications is warranted. The German interdisciplinary expert recommendations provided here are suggestions for the grading of EGFR-inhibitor-induced skin reactions as well as general, grade-specific and stage-adapted treatment approaches for the treatment of skin reactions induced by EGFR inhibitors. The most important conclusion is that EGFR-inhibitorinduced skin reactions can be effectively treated at all stages and at all grades [26] . All dermatologic effects induced by EGFR inhibitors are supposed to be reversible.
Concerning the grading of skin toxicity, we recommend using the NCI-CTCAE version 4.0 grading scale, but one has to be aware of the worldwide dissemination of version 3.0 and its usage in clinical trials until recently. Importantly, in our opinion, in addition to the NCI-CTCAE grading scale, grading should be strictly based on the grade of severity and not on the pattern of distribution. Since Bauer et al. [77] had observed an underreporting of dermatologic adverse drug reactions in colorectal cancer clinical trials due to incorrect assessment of skin reactions, a continuous training of physicians in correct grading should be obligatory and adverse effects reporting standards for oncology clinical trials should be developed [78] .
Concerning treatment strategies, one should always keep in mind that dermatologic care is supportive and aims at maintaining quality of life while continuing EGFR inhibitor treatment [15, 55] . Our recommendation on the start of treatment of skin reaction is to intervene as early as possible at the first sign of dermatologic reactions. Basic skin care combined with a specific therapy adapted to the stage and grade of skin reaction is recommended. Topical antibiotics like metronidazole, erythromycine or nadifloxacin are recommended at the early onset of skin reactions; systemic oral antibiotics, i.e. the synthetic tetracyclines doxycycline or minocycline, are recommended for grade ‡ 2 dermatologic toxic effects due to their anti-inflammatory properties [71, 72] . In most cases, this approach allows patients to continue anti-EGFR treatment without interruption, dose delay or drug discontinuation [27] and should aim to maintain quality of life of the patient. Our recommendations are summarized in Table 5 . Importantly, individual clinical judgement must always be provided when reviewing the treatment algorithms.
Recently, topical use of menadione, a vitamin K 2 precursor [79, 80] or vitamin K1 cream containing urea and 0.1% K1 vitamin applied twice daily [81] showed effectiveness in downstaging of EGFR-inhibitor-induced rash. Due to results from the STEPP trial, prophylactic treatment seems to be a promising management strategy [64] . Nevertheless, the expert panel concluded that confirmatory trials, e.g. randomized phase 3 trials, are required in order to recommend prophylactic treatment for routine clinical practice. In the future, however, if data on prophylactic treatment are more robust, this might become first choice.
Importantly, the optimal treatment of skin toxicity may only be achieved by a cooperation of medical oncologists, dermatologists and pharmacists. Considering evidence-based treatment approaches, prospective controlled clinical trials are warranted to further optimize the treatment of anti-EGFRinduced skin reactions.
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